MX389934B - ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION. - Google Patents

ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION.

Info

Publication number
MX389934B
MX389934B MX2016016339A MX2016016339A MX389934B MX 389934 B MX389934 B MX 389934B MX 2016016339 A MX2016016339 A MX 2016016339A MX 2016016339 A MX2016016339 A MX 2016016339A MX 389934 B MX389934 B MX 389934B
Authority
MX
Mexico
Prior art keywords
growth factor
organ
neuropeptide
wound healing
repitellization
Prior art date
Application number
MX2016016339A
Other languages
Spanish (es)
Other versions
MX2016016339A (en
Inventor
Sarmiento Alberto Eduardo Ayala
HERNÁNDEZ Jesús Enrique ESTUDILLO
Rojas Rafael Rodríguez
Original Assignee
Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V filed Critical Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V
Priority to MX2016016339A priority Critical patent/MX389934B/en
Priority to PCT/IB2017/057673 priority patent/WO2018104874A1/en
Publication of MX2016016339A publication Critical patent/MX2016016339A/en
Publication of MX389934B publication Critical patent/MX389934B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the pharmaceutical and biotechnology industry for wound healing and organ re-epithelisation treatments. The advantages of the invention with respect to compositions of the prior art are that, in addition to accelerating the healing process, the composition makes it possible to speed up organ re-epithelisation without generating hyperplasia, thereby improving organ quality following a deterioration. The composition is formed by a growth factor and a neuropeptide. The growth factor is epidermal growth factor, while the neuropeptide is neurotensin. The composition contains epidermal growth factor in a concentration of 0.00001-10 mg/ml and neurotensin in a concentration of 0.00001-10 mg/ml. The combination can have any pharmaceutical form and can be administered by any route of administration.
MX2016016339A 2016-12-09 2016-12-09 ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION. MX389934B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2016016339A MX389934B (en) 2016-12-09 2016-12-09 ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION.
PCT/IB2017/057673 WO2018104874A1 (en) 2016-12-09 2017-12-06 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016016339A MX389934B (en) 2016-12-09 2016-12-09 ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION.

Publications (2)

Publication Number Publication Date
MX2016016339A MX2016016339A (en) 2018-06-08
MX389934B true MX389934B (en) 2025-03-20

Family

ID=62491777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016339A MX389934B (en) 2016-12-09 2016-12-09 ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION.

Country Status (2)

Country Link
MX (1) MX389934B (en)
WO (1) WO2018104874A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211569T1 (en) 2016-06-07 2022-01-21 Modernatx, Inc. Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
CA3080592A1 (en) 2017-10-31 2019-05-09 Modernatx, Inc. Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
JP2022532078A (en) * 2019-05-08 2022-07-13 アストラゼネカ アクチボラグ Compositions for skin and wounds and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253374T1 (en) * 1998-03-07 2003-11-15 Dae Woong Pharma TOPICAL COMPOSITION CONTAINING HUMAN EPIDERMAL GROWTH FACTOR
CU23043A1 (en) * 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION CONTAINING EPIDROMIC GROWTH FACTOR (EGF) FOR THE PREVENTION OF AMBASSATION OF DIABETIC FOOT.
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
CU23388B6 (en) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION OF MICROSPHERES TO PREVENT AMPUTATION OF THE DIABETIC FOOT

Also Published As

Publication number Publication date
MX2016016339A (en) 2018-06-08
WO2018104874A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
CL2018003178A1 (en) Pharmaceutical composition
BR112018076114A2 (en) apremilast topical compositions
BR112014021498A2 (en) compound, composition and method for treating a disease associated with covalently closed circular DNA formation
EA201990820A1 (en) METHODS FOR TREATING MITOCHONDRIAL AND METABOLIC DISORDERS
EA201791537A1 (en) PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
MX2023014492A (en) COMPOUNDS USEFUL IN THERAPY FOR HIV.
PE20200600A1 (en) COMPOSITIONS AND METHODS TO PROMOTE HAIR GROWTH WITH MPC INHIBITORS
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
MX389934B (en) ADJUVANT COMPOSITION OF A GROWTH FACTOR AND A NEUROPEPTIDE TO ACCELERATE WOUND HEALING AND ORGAN REPITELLIZATION.
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
CL2021002149A1 (en) Formulation of afabicin, method to elaborate the same
EA201991341A1 (en) Phenytoin FOR LOCAL USE FOR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
MX2020007760A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability.
MX382357B (en) METHODS AND COMPOSITIONS FOR TREATING SKIN FUNGAL INFECTIONS.
CL2019001746A1 (en) Aromatic carboxylic acid amides
BR112017008033A2 (en) For oral administration the pharmaceutical composition comprising the taxane
EA202090164A1 (en) Isotretinoin oral-mucous compositions and methods for their use
CL2020000859A1 (en) Gluconic acid derivatives to be used in the treatment and / or prevention of microbial infections.
BR112017014914A2 (en) combined therapy for pulmonary hypertension
PH12016500738A1 (en) Formulation for gonadotropins
CO2020004244A2 (en) Methods and compositions for treating chronic lung diseases
AR115883A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADDICTION TO PSYCHOACTIVE SUBSTANCES AND / OR FOR THE PREVENTION OF RELIPS TO SUCH ADDICTION
BR112015023368A2 (en) Vitamin B12 deficiency treatment method
EA202091561A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT